B. Riley Securities maintains Agenus at Buy, raises price target to $16 from $14
B. Riley Securities kept its Buy rating on Agenus and increased its price target to $16 from $14, suggesting a 123.8% upside from the Nov 6 close of $7.15.
AGENUS INC
Agenus is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. Its primary business is immuno-oncology, with botensilimab and balstilimab as its lead clinical program, studied alone and in combination. The company also has earlier-stage antibody programs and discovery platforms for identifying targets, generating antibodies and selecting candidates. Through its subsidiary SaponiQx, Agenus develops saponin-based vaccine adjuvants, including QS-21 STIMULON and cultured plant cell-derived cpcQS-21. It also holds an equity investment in MiNK Therapeutics. Agenus uses internal research, translational, clinical and regulatory capabilities, along with collaborations, to advance product candidates. It receives payments under licensing and collaboration agreements, including milestones and royalties, and recognizes revenue from BOT and BAL supplied through authorized access programs. SaponiQx develops and manufactures adjuvants. Agenus is headquartered in Lexington, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $AGEN in the last 7 days.
No SEC Form 4 filings for $AGEN in the last 30 days.
See all $AGEN insider activity →B. Riley Securities kept its Buy rating on Agenus and increased its price target to $16 from $14, suggesting a 123.8% upside from the Nov 6 close of $7.15.
Agenus Inc. reported that 51% of 123 patients with a specific type of colorectal cancer survived at least 18 months on its BOT+BAL treatment, with an estimated 59% of those alive at three years. This is a post-hoc analysis of prior Phase 1b results, not a new trial.
Agenus plans to begin a Phase 3 trial for colon cancer treatment, with enrollment starting soon. The trial, involving 850 patients, will compare the company's treatment with standard care. Additional funding of up to $255 million is contingent on trial milestones, with enrollment expected to complete by late 2028 and results by 2030.
Recent AGEN coverage spans financial news, earnings and technology.
Analyst upgrade and higher target suggest upside potential.
The data modestly supports durability of BOT+BAL in a defined MSS colorectal subgroup, but it is explicitly post-hoc and not a new controlled readout.
Financing linked to trial milestones could boost cash runway if enrollment proceeds, but also introduces dilution risk.
Earnings beat may lift sentiment and support short-term price upside.
Positive clinical data and regulatory clearance likely improve Agenus' near‑term valuation.
AlphAI scores every news story that mentions AGEN with an AI model for sentiment and relevance, and aggregates insider trades from AGENUS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
B. Riley Securities kept its Buy rating on Agenus and increased its price target to $16 from $14, suggesting a 123.8% upside from the Nov 6 close of $7.15.
Agenus Inc. reported that 51% of 123 patients with a specific type of colorectal cancer survived at least 18 months on its BOT+BAL treatment, with an estimated 59% of those alive at three years. This is a post-hoc analysis of prior Phase 1b results, not a new trial.
Agenus plans to begin a Phase 3 trial for colon cancer treatment, with enrollment starting soon. The trial, involving 850 patients, will compare the company's treatment with standard care. Additional funding of up to $255 million is contingent on trial milestones, with enrollment expected to complete by late 2028 and results by 2030.
Agenus (AGEN) reported Q3 EPS of -$0.18, beating estimates by $0.08, with revenue of $33.7M, exceeding expectations of $28.23M. The stock is up 0.14% in 3 months and 75.52% in 12 months. InvestingPro rates its financial health as 'good performance'.
AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engageme
Agenus Inc. (AGEN) reported Q3 revenue of $31.5M, up from $30.2M YoY, with net income of $2.8M. The company announced plans to enroll the first patient in its Phase 3 ROBBIN trial for colon cancer in Q1 2027, with interim results expected in Q4 2027. Two Phase 2 studies showed 30% pathologic complete response rates. Armenia granted marketing authorization for botensilimab and balstilimab. AGEN has $86.9M in cash and raised $85M in a private placement.
Agenus Inc. (AGEN) reported positive Phase 2 UNICORN trial results for botensilimab and balstilimab in colon cancer. In pMMR/MSS patients, 36% achieved major pathologic response, 29% complete response. All dMMR/MSI-H patients responded, with 13 complete responses. No recurrences at 12 months. Agenus plans a Phase 3 trial.
Agenus reported 100% major pathologic response in a 14-patient dMMR/MSI-H cohort, with 93% achieving complete response. At the 2026 cutoff, no recurrences occurred, and 12-month event-free survival was 100%. The company plans a Phase 3 trial for high-risk colon cancer.
Agenus Inc. reported Phase 2 NEOASIS study results, showing 83% MPR and 72% pCR in 18 dMMR colon cancer patients treated with botensilimab plus balstilimab. The company aims to expand use across tumors, pending further studies and regulatory discussions.
Chardan Capital kept its Buy rating on Agenus with a $40 price target, implying a 525% upside from the Oct 21 close. The firm cited Agenus's strong development pipeline, including botensilimab and balstilimab, and positive clinical data expectations from studies like NEST and UNICORN.